Dulaglutide, sold under the brand name Trulicity and made by Eli Lilly, is a prescription medication approved by the FDA for managing type 2 diabetes and reducing the risk of serious cardiovascular events. It belongs to a class of drugs called GLP-1 receptor agonists, which work by mimicking a natural hormone that helps regulate blood sugar, appetite, and feelings of fullness. One of the most practical features of dulaglutide is its dosing schedule: patients inject it just once a week, which makes it far more convenient than medications that require daily use. Researchers studying dulaglutide for diabetes and weight-related outcomes began to notice something unexpected in their data. People taking dulaglutide also appeared to be drinking less alcohol, and that pattern was consistent enough to warrant serious scientific investigation.
One of the most striking early signals came from a case report published in Frontiers in Psychiatry in 2025. A 44-year-old man who had been drinking roughly 90 beers per month was prescribed dulaglutide to treat pre-diabetes. Nobody told him the drug might affect his drinking. Nobody put him in a treatment program for alcohol. Yet over the following weeks, he noticed his cravings for alcohol had faded dramatically and his consumption dropped. When he lost his insurance and had to stop taking dulaglutide, his alcohol use climbed back to near where it had been before. That reversal is important because it points directly to the drug as the cause, not chance or lifestyle changes. Around the same time, researchers analyzing data from a clinical trial called the SKIP trial found that participants taking dulaglutide drank 29 percent less alcohol than those on placebo over 12 weeks, a statistically significant difference that held up even after adjusting for other factors.
What Did The Clinical Research Show About Dulaglutide And Alcohol Use?
The SKIP trial was a 12-week clinical study designed to test whether dulaglutide could help people quit smoking. The primary goal of helping participants stop smoking was not achieved, but researchers had collected detailed data on alcohol consumption as a secondary measure, and when they analyzed those numbers, the findings were striking. Among 151 participants who drank alcohol at the start of the trial, those taking dulaglutide consumed 29 percent less alcohol than those taking placebo, a difference that was statistically significant with a p-value of 0.04. After adjusting for education level, the reduction grew to 36 percent with an even stronger p-value of 0.004. This secondary analysis was published in JCI Insight in 2023 by Probst and colleagues.
What makes this finding especially meaningful is that the reduction in alcohol use was entirely independent of smoking status. Researchers specifically tested whether the drop in drinking could be explained by participants also cutting back on cigarettes, and it could not. The alcohol effect stood on its own. This matters because it suggests dulaglutide is doing something directly to the brain circuits that drive cravings for alcohol, rather than producing a general suppression of all reward-seeking behavior through quitting smoking. Preclinical research published in Translational Psychiatry in 2020 by Vallof and colleagues adds further context: nine weeks of once-weekly dulaglutide reduced alcohol intake in both male and female rats, and male rats continued to drink less for three full weeks after the drug was stopped.
What Does Population-Level Data Show About Dulaglutide And Addiction Risk?
Beyond clinical trials, researchers have examined large real-world datasets to see whether people prescribed dulaglutide develop fewer substance use problems. A nested case-control study using the All of Us research database, published in Frontiers in Psychiatry in 2026, found that dulaglutide was associated with an 82 percent reduction in the odds of developing alcohol use disorder, with an odds ratio of 0.18. The same analysis found 64 percent lower risk of opioid use disorder, 74 percent lower odds of cocaine use disorder, and 69 percent lower odds of nicotine use disorder. These are large, consistent reductions across multiple substance categories, which suggests dulaglutide may be affecting a shared mechanism in the brain rather than acting on any one substance in isolation.
A separate large cohort study published in The BMJ in 2026 examined over 606,000 veterans and found that GLP-1 drugs including dulaglutide were associated with 40 percent fewer overdoses and 50 percent fewer drug-related deaths compared to veterans not taking these medications. While this study covered the broader GLP-1 drug class rather than dulaglutide alone, the scale and consistency of the findings reinforce the idea that this type of medication may offer meaningful protection against some of the most serious harms of addiction. Researchers believe the mechanism involves sustained GLP-1 receptor engagement in brain reward circuits, which dampens the dopamine response that alcohol and other drugs normally trigger.
What is dulaglutide and how does it work?
Dulaglutide is a once-weekly injectable medication approved for type 2 diabetes and cardiovascular risk reduction. It mimics GLP-1, a natural hormone that helps regulate blood sugar and appetite. In the brain, GLP-1 receptors are found in reward circuits. Dulaglutide appears to dampen the dopamine release that drugs and alcohol normally trigger, which may explain why people report reduced cravings while taking it.
Can dulaglutide reduce alcohol cravings?
Early research suggests it can. A secondary analysis of the SKIP clinical trial found that participants taking dulaglutide drank 29 to 36 percent less alcohol than those on placebo over 12 weeks. A published case report described a man whose alcohol cravings faded while on dulaglutide and returned when he stopped. Population studies also link dulaglutide use to dramatically lower rates of alcohol use disorder, though more dedicated trials are needed.
Is dulaglutide used in addiction treatment programs?
Not yet as a standard treatment. Dulaglutide is not FDA-approved for addiction or alcohol use disorder, and it is not currently part of established addiction treatment protocols. However, the emerging research is promising enough that scientists are actively investigating GLP-1 drugs for this purpose. If you are exploring all available options for recovery, speaking with a physician about medications that may support your treatment plan is always a reasonable step.
